| 0.111 0 (0%) | 02-11 15:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.15  |
1-year : | 0.17 |
| Resists | First : | 0.12 |
Second : | 0.14 |
| Pivot price | 0.1  |
|||
| Supports | First : | 0.09 | Second : | 0.08 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.1 |
| MA(100) : | 0.21 |
MA(250) : | 2.1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.3 |
D(3) : | 11.3 |
| RSI | RSI(14): 43.7 | |||
| 52-week | High : | 10.13 | Low : | 0.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NEXI ] has closed above the upper band by 13.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 91.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.14 - 0.14 | 0.14 - 0.14 |
| Low: | 0.1 - 0.1 | 0.1 - 0.1 |
| Close: | 0.11 - 0.11 | 0.11 - 0.11 |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Thu, 15 Aug 2024
NexImmune shareholders approve company dissolution - Investing.com
Fri, 12 Jul 2024
NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace
Thu, 11 Jul 2024
What Is Going on With NexImmune (NEXI) Stock Today? - InvestorPlace
Tue, 09 Jan 2024
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation - InvestorPlace
Fri, 01 Dec 2023
Why Is NexImmune (NEXI) Stock Up 353% Today? - InvestorPlace
Fri, 01 Dec 2023
NEXI Stock Halted: What’s Going on With NexImmune Shares Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 10.7 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -18.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -72.7 % |
| Return on Equity (ttm) | -233 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -11.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|